Linperlisib and rituximab for relapsed or refractory indolent non-Hodgkin lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new targeted therapy (linperlisib) combined with rituximab, an existing antibody drug, for people with a slow-growing type of non-Hodgkin lymphoma that has come back or not responded to previous treatments. The goal is to see if this combination is safe and effective in controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have tried at least one previous cancer treatment.
- You have been treated with rituximab (or a similar drug) before.
- You have at least one tumor that can be measured on a scan (for example, a lymph node larger than 1.5 cm or another tumor larger than 1.0 cm).
- You have not taken a PI3K inhibitor (a type of targeted therapy) before.
- You do not have any serious side effects from your previous treatments that haven't gone away.
- You do not have active hepatitis B, hepatitis C, or HIV, and you haven't had an infection requiring treatment in the last 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
This trial tests a combination of two oral drugs, chidamide and linperlisib, for people with follicular lymphoma that has not responded to or come back after at least two prior treatments. The goal is to see if this combination can help shrink the lymphoma and stop it from growing.
This trial tests a new combination of two pills—linperlisib and an EZH2 inhibitor—for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease with manageable side effects.
This trial tests a new drug, linperlisib, combined with standard chemotherapy (CHOP) for people newly diagnosed with a rare type of T-cell lymphoma (nTFHL) who plan to have a stem cell transplant. It aims to see if this combination is safe and effective.
Hear when a new Relapsed/Refractory Indolent NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.